Evixapodlin NEW
| Price | $113 | $278 | $446 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: Evixapodlin | CAS No.: 2374856-75-2 |
| Purity: 99.07% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | Evixapodlin |
| Description | Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. |
| In vitro | Evixapodlin exhibits an ability to increase the production of IFN-γ and Granzyme B in both CD8+ and CD4+ T cells in individuals with chronic hepatitis B (CHB). Additionally, Evixapodlin enhances the frequency of Granzyme B-positive cells among HBV-specific CD8+ and CD4+ T cells.[1] |
| In vivo | Evixapodlin (10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment results in over 90% occupancy of the PD-L1 target on tumor cells. Evixapodlin effectively suppresses tumor growth in a mouse colorectal tumor model (MC38) that expresses human PD-L1.[1] |
| Storage | Store at low temperature,Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.89 mM), Sonication is recommended. 10% DMSO+90% Saline : 7.5 mg/mL (10.84 mM), Suspension. DMSO : 75 mg/mL (108.44 mM), Sonication is recommended. |
| Keywords | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | HBV | GS4224 | GS 4224 | Evixapodlin | Antiviral |
| Inhibitors Related | Dibenzofuran | Esculin | Doxorubicin hydrochloride | Hexane-2,5-dione | Lamivudine | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Sodium formate | Thiamine hydrochloride | (Tetrahydro-2H-pyran-4-yl)methanol | Nicotinamide | Tenofovir |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY